Magrolimab, a monoclonal antibody targeting CD47, demonstrated high response rates in phase Ib trials but was discontinued after the phase III ENHANCE-2 trial owing to lack of survival benefit and anemia-related toxicity (45–47). The gene discussed is CD47; the disease is anemia.